

Supplementary Table 1: Comparison between the characteristics of positive anti-N positive and anti-S (previous infection), negative anti-N and positive anti-S (previous vaccine), negative anti-N and anti-S (no previous exposure to Covid, neither infection nor vaccine) subjects at baseline (V0); data are expressed as number (%) or median (IQR)

*[footnote to Supplementary Table 1] *7 patients (2 with positive anti-N and anti-S; 3 with negative anti-N and positive anti-S; 2 with negative anti-N and anti-S) were excluded from this analysis due to previous/current methimazole treatment; **2 patients with positive anti-N and anti-S, 3 patients with negative anti-N and positive anti-S, and 2 patients with negative anti-N and anti-S) receiving previous/current methimazole treatment were included. Abbreviations: anti-N: IgG against nucleocapside; anti-S: IgG against the spike protein; IQR: interquartile range; BMI: body mass index; SBP: systolic blood pressure; DBP: diastolic blood pressure; HR: heart rate; ESR: Erythrocyte Sedimentation Rate; CRP: C-reactive protein; TSH: Thyroid-stimulating hormone; fT3: free triiodothyronine; fT4: free thyroxine; Tg: Thyroglobulin; TPOAb: Thyroid Peroxidase Antibodies; TgAb: Thyroglobulin Antibodies; TRAb: Anti-TSH receptor antibodies; BSA: body surface area; NSAIDs: non-steroidal anti-inflammatory drugs; V0: baseline.*

	anti-N+ and anti-S+ <i>n</i> = 7	anti-N- and anti-S+ <i>n</i> =23	anti-N- and anti-S- <i>n</i> =22	P value
Age (years)	52.1 (43.5-59.7)	51.5 (41.9-57.9)	48.6 (40.3-53.8)	0.60
BMI (kg/m ²)	23.8 (20.5-24.5)	24.3 (21.2-26.3)	23.6 (21.0-25.2)	0.79
Gender F <i>n</i> (%)	6 (85.7%)	17 (73.9%)	19 (86.4%)	0.53
Previous thyroid disease <i>n</i> (%)	2 (28.6%)	5 (21.7%)	8 (36.4%)	0.56
Physical examination				
SBP (mmHg)	110 (102-114)	120 (110-135)	120 (110-130)	0.20
DBP (mmHg)	70 (66-81)	80 (70-83)	75 (70-80)	0.32
HR (bpm)	82 (72-92)	80 (68-88)	80 (72-100)	0.70
Respiratory symptoms <i>n</i> (%)	4 (57.1%)	3 (13.6%)	6 (27.3%)	0.07
Temperature >37.5°C <i>n</i> (%)	5 (71.4%)	6 (27.3%)	6 (27.3%)	0.07
Temperature (°C)	36.0 (36.0-36.8)		36.5 (36.1-37.0)	0.25
Increased thyroid consistency <i>n</i> (%)	4 (66.7%)	10 (43.5%)	10 (45.4%)	0.77
Pain at palpation <i>n</i> (%)	3 (50.0%)	10 (43.5%)	12 (60.0%)	0.80
Pain before diagnosis (>15 days) <i>n</i> (%)	5 (71.4%)	16 (69.6%)	15 (68.2%)	0.89
Current pain at V0 <i>n</i> (%)	3 (42.9%)	16 (69.6%)	14 (63.6%)	0.44
Biochemical parameters				
ESR (mm)	29 (17-41)*	46 (25-69)	57 (40-95)*	0.04
CRP (mg/dl)	0.5 (0.2-3.3)	1.2 (0.5-4.0)	1.7 (0.5-5.6)	0.32
TSH (μUI/ml)*	0.30 (0.02-1.46)	0.41 (0.01-2.37)	0.06 (0.01-0.69)	0.63
ft3 (pg/ml)*	3.10 (2.61-4.10)	3.89 (3.20-4.70)	4.25 (3.03-6.16)	0.24
ft4 (pg/ml)*	12.4 (11.0-20.4)	13.2 (10.1-22.6)	14.0 (10.2-28.6)	0.74
Tg (ng/ml)	37.0 (1.7-92.1)	14.7 (10.4-68.2)	16.4 (4.5-67.4)	0.95
Thyrotoxicosis <i>n</i> (%)**	4 (57.1%)	15 (71.4%)	16 (76.2%)	0.63
Positive TPOAb <i>n</i> (%)	1/7 (14.3%)	3/18 (16.7%)	2/21 (9.5%)	0.80
Positive TgAb <i>n</i> (%)	0/2 (0%)	2/17 (11.8%)	7/21 (33.3%)	0.11
Positive TRAb <i>n</i> (%)	2/5 (40.0%)	3/16 (18.8%)	2/18 (11.1%)	0.33
US characteristics				
Thyroid volume-to-BSA ratio	8.1 (6.9-10.7)	8.3 (6.8-9.8)	8.2 (5.0-11.9)	0.94
Increased thyroid volume <i>n</i> (%)	3/5 (60.0%)	11/20 (50.0%)	11/21 (52.4%)	0.92
Thyroid inhomogeneity <i>n</i> (%)	7/7 (100%)	18/20 (90.0%)	21/21 (100%)	0.23
Previous medical treatment (before V0)				
Beta blockers <i>n</i> (%)	1 (14.3%)	4 (17.4%)	2 (9.1%)	0.82
NSAIDs <i>n</i> (%)	3 (42.9%)	6 (26.1%)	8 (36.4%)	0.44
Steroids <i>n</i> (%)	5 (71.4%)	3 (26.1%)	3 (13.6%)	0.11
Levothyroxine <i>n</i> (%)	1 (14.3%)	0 (0%)	1 (4.5%)	0.39
Methimazole <i>n</i> (%)	1 (14.3%)	1 (4.3%)	1 (4.4%)	0.56

*post-hoc: p=0.011

Supplementary Table 2: Comparison between medical management and outcome parameters of anti-N positive and anti-S positive (previous infection), anti-N negative and anti-S positive (previous vaccine), anti-N negative and anti-S negative (no previous exposure to Covid, neither infection nor vaccine) subjects; data are expressed as number (%) or median (IQR)

[footnote to Supplementary Table 2] *Abbreviations: anti-N: IgG against nucleocapside; anti-S: IgG against the spike protein; IQR: interquartile range; NSAIDs: non-steroidal anti-inflammatory drugs; V1: visit at 1 month; V2: visit at 3 months; V3: visit at 6 months; V4: visit at 12 months.

	anti-N+ and anti-S+ <i>n</i> = 7	anti-N- and anti-S+ <i>n</i> =23	anti-N- and anti-S- <i>n</i> =22	P value
Medical treatment during study period				
Beta blockers <i>n</i> (%)	1 (14.3%)	4 (17.4%)	2 (9.1%)	0.82
NSAIDs <i>n</i> (%)	3 (42.9%)	6 (26.1%)	8 (36.4%)	0.44
NSADs duration (days)	8 (2-8)	4 (2-8)	7 (2-16)	0.58
Steroids <i>n</i> (%)	6 (85.7%)	13 (56.5%)	14 (63.6%)	0.14
Steroids duration (days)	29 (19-74)	51 (17-95)	35 (24-59)	0.75
Cumulative steroids dosage (mg)	284 (175-1075)	450 (231-1182)	562 (403-913)	0.74
Levothyroxine <i>n</i> (%)	1 (14.3%)	0 (0%)	2 (2.2%)	0.39
Thyroid functionality evolution				
Transient hypothyroidism at V1, V2, or V3	2/5 (40.0%)	9/23 (39.1%)	6/22 (27.3%)	0.65
Normal thyroid function at V4	3/3 (100%)	15/17 (88.2%)	12/17 (70.6%)	0.38
Hypothyroidism at V4 (requiring LT4 therapy)	0/3 (0%)	1/17 (5.9%)	2/17 (11.8%)	0.80